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AIL4 Medical/Scientific Statement
Special Report
The Report of the American Heart
Association Task Force on Strategies to
Increase Federal Research Funding
Michael R. Rosen, MD, and Harold C. Strauss, MD, Chairmen
Holly G. Atkinson, MD; Alfred P. Fishman, MD; Charles K. Francis, MD;
Arnold M. Katz, MD; and August M. Watanabe, MD, Members
Francois M. Abboud, MD, and Myron L. Weisfeldt, MD, Ex Officio
William F. Friedman, MD, and Bernadine P. Healy, MD, Advisors
Scott D. Ballin, JD; Claudia Louis; Rodman D. Starke, MD; and Wallace G. Frasher, MD, Staff
The Charge
The charge of the task force is summarized below:
1. To examine present and projected patterns of
federal biomedical research funding
The task force limited its review to cardiovascular
research and training and the relationship of the
research community to the National Heart, Lung,
and Blood Institute (NHLBI). The task force recog-
nizes that the NHLBI is not the sole federal agency
funding cardiovascular research, but it is the major
one. Data from other agencies were considered only
when comparisons were sought. Similarly, although
the primary concern of the task force is research
funding in the United States, data from other coun-
tries were also considered when appropriate.
To discern present patterns, the task force
reviewed data from the National Institutes of Health
(NIH) and the American Heart Association's Office
of Public Affairs. While these data clearly depict the
targeting of funds for research and training for more
than 10 years, they do not necessarily depict the
expenditure.
Projecting future patterns was more difficult. The
task force could not find a clear statement of federal
research management policy for the next decade but
only an outline of possible reactions to anticipated
budgetary constraints. Hence, the task force used
NHLBI models that incorporate a yearly 3.7% incre-
ment in the budget.
2. To evaluate options available to the American
Heart Association (AHA) to maintain adequate fed-
eral support for cardiovascular research
Before considering the options available to the
AHA, the task force examined whether support of
research by the federal government is an expenditure
of tax dollars that benefits society. The task force
considered four types of benefit:
* Improved health care: The task force traced the
relation between federal funding, scientific progress,
and improved health care. This relation was evalu-
ated in terms of reduction in mortality, alleviation of
suffering, improved quality of life, and increased
efficiency of health care delivery.
* Scientific leadership: The relation between fed-
eral funding and research progress and its impor-
tance to the worldwide scientific community as
reflected by scientific publications was considered.
The US scientific community was found to have
played a pivotal international role in scientific discov-
ery and leadership.
* Economic gain: The relation of scientific prog-
ress to the function of industry and its effect on
economic health was considered. First, the link
between NIH-sponsored research and the resultant
patents that yielded potentially beneficial therapies
was examined. (Although the task force recognized
that patents in other fields [e.g., diagnostic] benefit
health care delivery and the economy, this potentially
important area was not reviewed.) Second, the task
force examined the extent to which federal funding
has supported the training of scientists employed by
industry.
* Intellectual enrichment: Although the task force
believes that all forms of intellectual enrichment are
important to society, the task force did not attempt to
assign it a specific value.
Having considered the four types of benefits, the
task force established that society profits from fed-
Correspondence should be addressed to the Office of Scientific
Affairs, American Heart Association, 7320 Greenville Avenue,
Dallas, TX 75231.
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TABLE 1. Summary Research Funding for Selected Institutes*
1982 1983 1984 1985 1986 1987 1988 1989 1990
NHLBI total $ in 1,000s 559,606 624,065 705,064 803,810 806,433 929,981 965,283 1,045,508 1,072,354
NHLBI minus AIDS 559,601 622,863 700,193 794,487 806,433 912x737 940,398 1,007,420 1,030,298
NHLBI number of competing
RPGs funded 765 748 852 901 886 966 851 698 601
Average duration of grant (yrs.) 3.4 3.3 3.4 3.6 4.1 4.1 - - -
% grants >5 yrs. 17 15 14 28 30 51 55 57 -
NHLBI budget
% increment - 11.5 13 14 2.8 12.5 3.8 8.3 2.6
CF NCI - 5.1 9.6 8.9 4.3 14.2 9.7 6.9 4.1
CF NINDS - 11.6 13.4 17.9 4.6 18.3 NA 2.8 4.0
NHLBI non-AIDS budget
% increment - 11.3 12.4 13.5 1.5 13.2 3.0 7.1 2.3
CF NCI - 9.4 9.0 8.1 1.2 14.9 2.9 5.0 2.5
CF NINDS - 11.3 13.2 18.1 4.5 17.8 NA 2.7 3.4
*Data from National Institutes of Health and American Heart Association, Office of Public Affairs.
NHLBI, National Heart, Lung, and Blood Institute; AIDS, acquired immunodeficiency syndrome; RPGs, newly submitted and competing
continuation Research Project Grants; NCI, National Cancer Institute; NINDS, National Institute of Neurological Disorders and Stroke.
eral tax dollars spent on research support. The task
force then evaluated the impact of past and present
policy on science, health, and the economy, and
considered the options available to the AHA to
maintain adequate federal research support.
3. To make recommendations to the AHA's Board
of Directors for appropriate action
Two forms of action were recommended, one
involving the AHA alone and the second requiring a
coordinated effort among diverse interested parties.
The two actions are in no way mutually exclusive.
The Report
Pattems of Federal Research Funding
Research grants. Present patterns of NHLBI
funding.* The NHLBI budget has grown from $560
million in 1982 to $1,072 million in 1990, with most
growth occurring before 1986 (Table 1). From 1982
to 1987 (with the exception of 1986), the funding
component of the NHLBI budget grew by more than
10% per year. Since 1987, the budget has increased
less than 10% per year, and the proposed increment
for 1991 is only 3.7%, which is less than the projected
rate of inflation. (See Table 1 for additional data
from the National Cancer Institute and the National
Institute for Neurological Disorders and Stroke.)
The impact of this pattern of research support on
the number of research grants funded, administrative
reductions in the approved budgets of funded grants,
and the magnitude of these budgetary reductions was
considered.
NUMBER OF GRANTS FUNDED. As seen in Table 1,
the NHLBI funded 765 new and competing continu-
ation applications in 1982. The number funded
peaked in 1987 with 966 awards, followed by a
dramatic decrease to 698 awards in 1989 and 601
awards projected for 1990. This decline in new
awards is paralleled and explained, in part, by the
increased duration of the majority of noncompeting
continuation applications. For example, in 1982, the
NHLBI's average award period was 3.3 years, and
only 17% of NHLBI awards were funded for 5 years
or more. In 1987, the average length of the grant had
increased to 4.1 years, with 51% of awards funded for
5 years or more. By 1989, 56% were funded for 5
years or more. Despite the increased duration of
funding and cost of research, the 33% decline in
overall new and competing applications funded since
1987 and the reduction in monies delivered to funded
grants, as detailed below, exemplifies a system that is,
at best, attempting to maintain a status quo rather
than permitting growth. It is unfortunate that this
restriction is occurring at a time when new technol-
ogies continue to expand the opportunity for substan-
tial new discoveries.
ADMINISTRATIVE REDUCTIONS IN APPROVED BUD-
GETS OF FUNDED GRANTS. Another stifling aspect of
the present situation is that significant, across-the-
board cuts have been levied on new and continuing
grants. To appreciate the impact of these budget
cuts, it is useful to consider how grants are reviewed
and recommended for funding. Applications submit-
ted by investigators (as investigator-initiated research
or in response to requests for applications) include a
description of the research to be performed, a budget
detailing the cost of the proposed research, and a
budget justification. Members of the peer review
committees, who discuss, judge, and vote on priority
scores for all applications, are viewed by the NHLBI
and the research community as representing excel-
lence in the areas of science to be reviewed. The
quality of the proposed research and the appropri-
ateness of the requested budgets are evaluated dur-
ing the review process. Reductions are recommended
in "overbudgeted" areas. Hence, the review process,
*Data obtained from Office of Public Affairs summary of NIH
funding patterns.
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TABLE 2. NHLBI Research Project Grants Budget Reductions*
Noncompeting Competing
Fiscal projects projects
Year (%) (%)
1985 -0.3 -1.5
1986 -4.7 -7.8
1987 -1.1 -10.9
1988 -9.6 -14.9
1989 -13.3 -11.5
1990** -14.5 -13.9t
1991** -11.0 -13.9
*Data from National Heart, Lung, and Blood Institute.
**Estimated. t1990 estimate of reductions necessary in compet-
ing research project grants is calculated with National Institutes of
Health total competing requirements model before fiscal year
begins. As a result, different reductions may be necessary when
applications to be funded are actually received and reviewed. For
National Heart, Lung, and Blood Institute, actual reductions in
fiscal year 1990 will be approximately 18.5%.
as originally designed, charges those individuals con-
sidered most capable of determining the quality of
the proposed research and its cost with recommend-
ing approval of the proposal and budget. In recent
years, this process has, by necessity, acquired a new
and increasingly restrictive dimension. Budget cuts
are now often based on administrative decision
rather than scientific justification as the result of
limited funds. This substantially undermines the abil-
ity of funded investigators to perform their approved
research.
IMPACT OF REDUCTIONS. To understand the mag-
nitude and impact of administrative reductions, the
task force considered the 1989-1990 fiscal year as an
example (Table 2). NHLBI grants are earmarked for
a yearly 4% increment in funding, which means that
in 1990, a 4% budget increase was planned for all
grants active in 1989. However, in 1989, funds for
research grants were cut by approximately 11.5% to
13.3%, depending on the type of grant. In 1990, the
NHLBI initially announced a budget reduction of
13.9% to 14.5%. However, based on adjustments
during the fiscal year (see Table 2), these reductions
are now estimated at 18.5%. Hence, nearly one fifth
of peer-reviewed budgets judged essential to the
performance of extramural research and funded by
the NHLBI in 1990 will not be funded.
Principal investigators of individual grants have
latitude in determining which budgetary areas are to
be reduced, and reductions may not be distributed
evenly across all budgetary categories. For example,
because of the time and expense involved in training
skilled individuals, some investigators may concen-
trate budgetary reductions in supplies. The result of
such an attempt to maintain salaries and keep a
research group intact is likely to be an even greater
decrease in productivity than might be projected by
the nearly 20% budget reduction, since the reduction
of funds for supplies may decrease the quantities of
supplies to the point that researchers may not have
enough materials with which to work.
To summarize, the duration of funding has
increased, but the number of new grants is not
growing. The net impact of the present funding policy
dictates that nearly 20% of research funded in the
past and for which funding is promised will no longer
be supported.
To appreciate the seriousness of this situation, it
must be understood that all research approved for
funding is not and never has been funded in toto.
Research is assigned a numerical grade of 1 (the
highest score) through 5 (the lowest score). The
availability of funds determines the lowest score that
can be funded. Moreover, because of differences in
grading among study sections, a normalization proc-
ess has been adopted to ensure uniform funding of a
certain percentile of grants. At present, the level of
funding hovers around the 15th percentile of
approved grants. As a result, only research that is
judged "outstanding" (priority score of 1.0-1.5) is
guaranteed funding. Research judged "excellent"
(1.5-2.0) may or may not be funded, and research
classifed as "good" (score of 2.0-2.5) is categorically
not funded. Although the task force supports the
view that outstanding research should be encouraged
and funded, there is concern that biomedical
research and overall progress may suffer if research
deemed "excellent" or "good" is not funded. In
addition, a system without room for research that is
"merely" good or even excellent may ultimately
strangle itself by limiting ideas and developments
that form the body of knowledge from which excel-
lence springs. Finally, while peer review committees
are quite capable of distinguishing inferior from
superior work, and even good from outstanding, they
cannot consistently or effectively distinguish the sub-
tleties that separate the "exceptionally good" from
the "excellent" or the "exceptionally excellent" from
the "outstanding."
At present, then, we are confronted with the
startling fact that only the top 18th percentile of
research judged worthy can be funded, and that
severe budgetary restraints are imposed on grants
that are funded.
Projections for future NHLBI funding. The
NHLBI has developed models to predict the future
of research support through the 1990s. Considering
budgetary constraints, the models attempt to reach
an acceptable compromise between maintaining a
status quo and providing an opportunity for growth.
The models assume a constant number of grants and
a distribution of award durations based on fiscal year
1989 and kept constant over time. The forecast is
bleak: Each year, 727 new and competing continua-
tion grants can be funded, with approximately 56% of
these funded for 5 years. The number of new grants
and competing continuations funded can be
increased to more than 800, but only if the number
funded for 5 years is decreased to about 40%. This
model illustrates the futility of a situation where
options for a solution are sorely lacking because the
projected budget increase is limited to 3.7% per year.
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Athough reducing the average grant duration will
increase the total number of grants to 800, this
solution merely creates an illusion rather than the
reality of more research being funded. In fact, inves-
tigators will spend and even waste time in submitting
renewal grant applications, and more time and
money will be required for review as well. The net
result cannot be construed as providing more
research, but rather, a greater number of grants of
less duration and, given increased administrative
demands, probably less output than could be
achieved with a smaller number of grants of longer
duration. For example, an investigator funded for 5
years in 1990 and again in 1995 will receive two grants
in the 1990s. However, if the investigator is funded
every 3 years (1990, 1993, 1996, and 1999), he or she
will be on record as receiving four grants throughout
the 1990s. Rather than doing more research, the
investigator is likely to do less, because he or she will
have to spend more time preparing grant applications
for submission and review.
In summary, these models predict only the illusion
of growth. To attain real growth, the system must be
fueled with sufficient monies to fund research that is
judged excellent or good and to permit approved
research to be conducted.
Training grants. To maintain excellence in biomed-
ical research, the brightest young people must be
encouraged to train in the sciences and must be given
the resources to enter a career that is exciting and
offers reasonable compensation and opportunity to
succeed. Obviously, education and training at the
primary and secondary school levels deserve high
priority to attract and prepare young persons for
careers in science. However, given its charge, the task
force focused on federally supported training at the
graduate and postdoctoral levels.
The NHLBI has a distinguished record of training
investigators. The success of training is monitored in
several ways, including publication in basic and clin-
ically oriented peer-reviewed journals and subse-
quent success in achieving NIH funding. Of note:
Scientists trained at NHLBI expense are not tracked
for their success in obtaining funding by private
foundations and other sources, nor is their contribu-
tion of knowledge and effort to industry acknowl-
edged.
The National Research Council and the Institute
of Medicine recently evaluated NIH support of train-
ing programs. A committee that met in 1988 and 1989
stated the following concerns:
There exists no complete inventory of the nation's
training mechanisms for biomedical and behavioral
science.... [For biomedical scientists] demand (Job
openings) has been growing relative to supply (new
PhDs) since the early 1980s. Industrial growth is over
twice the rate of academic employment growth....
Most new positions in biomedical science are
expected to be in industry. Unless demand growth
falls considerably from historical levels and/or enroll-
ments and degree production increase dramatically,
Application No.
0
1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990
Fiscal Year
- Received c,' Approved Funded
FIGURE 1. NHLBI institutional research training grants
received, approved, and funded. From National Heart, Lung,
and Blood Institute.
there is a projected undersupply of biomedical PhDs
into the next century. The undersupply is expected to
be even greater in the research and development
segment.... The committee recommends that to cor-
rect this trend, the level of predoctoral support be
5,200 full-time equivalent positions, up from the
current level of 3,681.1
In light of these perceived demands, what is the
status of NHLBI training awards? Figures 1 and 2
illustrate trends in the number of institutional
research training proposals received, approved, and
funded, and award rates from 1980 to 1989. Compa-
rable data are available for institutional training
grants, individual research training fellowships,
research career development awards, clinical investi-
gator awards, and physician-scientist awards.
Research training awards constitute 60% and
research career awards 40% of the NHLBI portfolio
of research training and development grants. The
data for institutional training grants show substantial
reductions in the number of grants awarded over the
past decade and a striking reduction in award rates
over the past 4 years. The number of individual
Award Rate (%l
100-
80o
40~~~~~~~~~~~g
1980 1981 1982 1983 1984 1985 1988 1987 1988 1989 1990
Fiscal Year
FIGURE 2. NHFLBI institutional research training grants
awarded between 1980 and 1989. From National Heart Lung,
and Blood Institute.
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70
60
0
Manage
1960 1965 1970 1975 1980 1985
FIGURE 3. Number and type of graduxate degrees awarded
between 1960 and 1985. From Healy.2 Reproduced with
permnission.
research fellowships has declined less over the dec-
ade, although award rates are currently in the 30% to
40% range, compared with award rates exceeding
70% in the early 1980s. Similarly, progressively fewer
research career development awards have been
funded. Of special concern is the decline in award
rates and the number of grants funded in the clinical
investigator and physician-scientist categories. For
example, 20 of 70 applicants in the clinician-scientist
category were funded in 1989. It is alarming that in
the entire nation, only 20 such individuals were
supported. Although an increase of approximately
10% in dollar support for research training and
career development is projected in the NHLBLs 1990
fiscal year, the increase in funds will support
increased stipend levels rather than more opportuni-
ties for training.
It is clear that continued progress in the cardiovas-
cular sciences requires support of research training.
This training must be responsive to expanding oppor-
tunities. Failure to support research training means
this nation must surrender its current leadership
position and import research achievement. It should
also be clear that concerns about the future of
research funding must be coupled with concerns
about training and development of young scientists.
The trends revealed by these data are ominous and
suggest a need for comprehensive strategies to
develop excellence in future generations of biomed-
ical scientists and to enhance funding levels for
research training and development.2 A problem
exists at all levels of education in the United States.
For example, among developed countries, US high
school students ranked in the bottom half for scien-
tific achievement. At the college level, degrees
awarded in business and management have
increased, whereas the number of physical sciences
degrees has plateaued and the number of biomedical
sciences degrees has decreased. The number of grad-
uate degrees awarded has even more stark implica-
tions for biomedical investigators. Figure 3 shows
that while law and business and management degrees
have increased, MD and PhD degrees have reached
a plateau.
TABLE 3. Dollar Estimates of Acquisition and Merger Transac-
tions and Research and Development Expenditures
Acquisitions Total research and
and mergers development
(US industry) (federal and private)
($ billion) ($ billion)
1977 22 43
1982 54 79
1985 180 108
1988 >200 125
From Healy.2 Reproduced with permission.
In part, success in education reflects effort
expended by the society responsible for motivating
and training its youth. Table 3 shows that in 1977, the
total research and development budget in the United
States was twice the budget for acquisitions and
mergers. By 1988, the proportions had practically
reversed, as research and development underwent a
threefold increase, whereas acquisitions and mergers
increased ninefold.
The number of applications to medical schools has
steadily decreased as have applicants' grade point
averages. Moreover, fewer graduates are selecting
careers in research, and all indications are that the
number of qualified applicants is declining at an
alarming rate.
Figure 4 tracks the attrition rates of scientists in
the biomedical field from 1974 to 1987 and relates
these data to the "refreshment rate":
During the 1980s the biomedical field averaged 4,500
job openings annually (1,080 scientists lost from
deaths and retirements, 620...lost from net mobility,
and growth requirements of 2,800). Average annual
biomedical PhD production during the period was
only 3,840. This contrasts sharply with the 1970s
when average annual job openings for all sources
were 3,660, and average annual PhD production was
3,520. Clearly the supply of new biomedical PhDs
has begun to fall short of the number of job openings
in the late 1980s after an extended period of approx-
imate balance.'
c
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FIGURE 4. Refreshment and attrition rates of biomedical
scientists from 1974 to 1987. From Biomedical and Behav-
ioral Research Scientists: Their Training and Supply,1p 34.
Reproduced with permission.
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FIGURE 5. Number of biomedical papers originating at 110
US medical schools (vertical axis) versus total NIH funds in
millions of dollars (horizontal axis). Adapted from McAllister
and Narin3 with permission.
If we are to remain a technologically advanced
nation rather than a nation of administrators and
managers, students at all educational levels must be
better prepared in the sciences. Moreover, career
opportunities in the sciences must be made more
attractive. This does not mean that all careers must
be equally rewarded financially. However, the stu-
dent considering a career in the sciences must under-
stand that a national commitment and policy exist
and that individual effort and commitment will be
rewarded - at least with the likelihood of career
advancement. To embark on a career dependent on
5-year grant reviews and where estimated quality of
research is overshadowed by unpredictable budget-
ary constraints that vary with the political winds is to
subject oneself to unnecessary and, in fact, uncon-
scionable risks. These risks already appear to have
been detrimental to the field of scientific endeavor,
which evidently appears less attractive as a way of life
than it once did.
Options to Maintain Adequate Federal
Cardiovascular Research Support
The task force attempted to answer several ques-
tions before evaluating options that might be avail-
able to the AHA. It was necessary to consider these
questions because their answers determined the level
of effort the AHA must expend. The task force
focused on cardiovascular research, but other disci-
plines are discussed as appropriate.
1. Is there a quantifiable relation between federal
research funding and scientific progress?
This question was considered by examining the
relation between federal support of research and
publication in scientific journals. McAllister and
Narin3 reviewed the numbers of papers originating at
110 US medical schools for which data on NIH
funding were available from 1973 to 1975 (see Figure
5). There was a strong linear correlation (r=0.95)
between the number of papers published (dependent
variable) and NIH dollars awarded (independent
variable). It was assumed that any deviation from a
TABLE 4. Top 10 Clinical Advances in Cardiovascular and
Pulmonary Medicine and Surgery in the Last 30 Years
Cardiac surgery (including open heart repair of congenital
defects and replacement of diseased valves)
Vascular surgery (including repair or bypass of obstructions or
other lesions in aorta, coronary, cerebral, renal, and limb
arteries)
Drug treatment of hypertension
Medical treatment of coronary insufficiency (myocardial
ischemia)
Cardiac resuscitation, defibrillation, cardioversion, and pacing in
patients with cardiac arrest, slow hearts, or serious arrhythmias
Oral diuretics (in treatment of patients with congestive heart
failure or hypertension)
Intensive cardiovascular and respiratory care units (including
those for postoperative care, coronary care, respiratory failure,
and disorders of newborns)
Chemotherapy and antibiotics (including prevention of acute
rheumatic fever and treatment of tuberculosis, pneumonias, and
cardiovascular syphilis)
New diagnostic methods (for earlier and more accurate
diagnosis of disease of cardiovascular and pulmonary-respiratory
systems)
Prevention of poliomyelitis (especially of respiratory paralysis
due to polio)
From Comroe and Dripps.' Reproduced with permission.
linear relation would indicate the effect of other
factors. In fact, the only institution identified as an
anomaly was Harvard, where the number of papers
exceeded that predicted by the linear relation. The
authors assume that this reflects other major sources
of support available to Harvard (including its endow-
ment), but this has not been tested. In addition,
because of the many institutions affiliated with it,
Harvard is not typical. Nonetheless, these data sup-
port the existence of a relation between federal
funding of research and a definable "product" (i.e.,
publication of scientific papers).
2. Are the results of basic research quantifiable
with respect to alleviation of suffering and improved
quality of life?
In 1976, Comroe and Dripps4 reported the most
comprehensive study addressing this question. They
asked 40 physicians to list the clinical advances most
important to patient care since the early 1940s. These
selections were then classified as cardiovascular or
pulmonary and sent to 40-50 specialists in those
areas, who were asked to rank the importance of
each advance and to add additional discoveries they
thought had been overlooked. The 10 top-ranked
advances are listed in Table 4. Comroe and Dripps
then met with 140 consultants to determine the
bodies of knowledge required for each of the 10 areas
of clinical advancement to occur. For those 10
advances, 137 essential bodies of knowledge were
identified. Some 4,000 articles related to these areas
were then considered, of which 2,500 were judged of
particular importance to at least one of the 137
bodies of knowledge. Of these, 529 were considered
key articles that were absolutely essential for a
clinical advance. A rating system was devised to
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TABLE 5. Goal of Authors of 529 Key Articles Judged Essential for Clinical Advance
Percent of total
Not clinically not clinically
Clinical advance Clinically oriented oriented Total oriented
Cardiac surgery 53 35 88 39.8
Vascular surgery 40 8 48 16.7
Hypertension 35 44 79 55.7
Coronary insufficiency 44 21 65 32.3
Cardiac resuscitation 24 16 40 40.0
Oral diuretics 19 24 43 55.8
Intensive care ... ... ...
Antibiotics 40 13 53 24.5
New diagnostic methods 41 53 94 56.4
Poliomyelitis 16 3 19 15.8
Total 312 217 529 41.0
*A key article is assigned to only one advance, even though it may have been essential to more than one. Because
practically every key article in intensive care was also essential to other advances, these articles were assigned elsewhere
(for example, to cardiac or vascular surgery, coronary insufficiency, resuscitation, or antibiotics). From Comroe and
Dripps.4 Reproduced with permission.
identify whether the goals of each of the key papers
were "clinically oriented" or "not clinically oriented"
research. It should be understood that the two cate-
gories do not indicate whether the research was
"basic." In fact, research in both categories could be
basic; however, research in the latter had no clinical
goal whatsoever. Table 5 incorporates the results of
this analysis, which indicates that a substantial per-
centage of the research that resulted in major clinical
advances had no clinically oriented goals. Moreover,
basic research, whether clinical or nonclinical in its
orientation, constituted over 60% of the total papers
reviewed.
Hence, as long ago as the mid-1970s, well-
quantified data reflecting the impact of basic
research on the most important areas of clinical
discovery were available. Nonetheless, one might
question the benefit of such advances. Despite the
altruistic desire to improve the lot of our fellow
humans, is the high cost of research justified at a time
of increasing prices and cost-consciousness? Cer-
tainly, there is no easy answer addressing all forms of
therapy. One approach has been to relate accom-
plishments in basic and clinical research to the length
of hospitalization of heart attack patients. In fact,
there has been a dramatic reduction in the duration
of hospitalization (associated with reduced morbidity
and reduced costs) after acute myocardial infarction.
It is important to note that the change in duration of
hospitalization has not been sudden and attributable
to a unique event unrelated to advances in science
(such as the advent of diagnosis-related groups).
Rather, it has been gradual. Between 1977 and 1987,
the average number of days in the hospital were,
respectively, 10.4, 10.2, 9.6, 9.4, 9.1, 8.8, 8.5, 7.6, 7.1,
6.7, and 6.5 (data from NHLBI). Additional data on
the cost of medical care and therapy are shown in
Table 6. The 5-year expected total cost per case of
acute myocardial infarction is estimated at $51,211.
In contrast, the expected 5-year cost for angioplasty
is $26,916, and for coronary bypass surgery, $32,465.
Hence, costly as they are, two therapies whose origins
lie in basic research individually are less expensive
than the disease left untreated.
Between 1977 and 1987, there was a decline in the
coronary heart disease death rate (see Figure 6) that
has, in turn, led to an 80% increase in the prevalence
of coronary heart disease (Figure 7) and a corre-
sponding 150% increase in morbidity costs (Figure
8). Although, at first glance, this increase in costs
appears staggering, the actual expense for the grow-
ing number of coronary heart disease patients is far
less than expected costs based on 1977 standards of
health care delivery (Figure 8). The decrease in
duration of hospitalization per person from 10.4 days
in 1977 to 6.5 days in 1987 has contributed to the
improved efficiency of health care delivery. More
important, the 1-year mortality rate in patients who
received early reperfusion therapy is markedly
reduced.5
TABLE 6. Medical Costs for Coronary Heart Disease Events
(5-Year Expected Total Cost Per Case)
Average
Coronary heart disease diagnoses cost
Acute myocardial infarction $51,211
Angina pectoris 24,980
Unstable angina pectoris 40,581
Sudden death 9,078
Nonsudden death 19,697
Coronary heart disease procedures
Angioplasty $26,916
Coronary bypass surgery 32,465
Data from Wittels E, Hay J, Gotto A: Medical costs of coronary
artery disease in the United States.Am J Cardiol 1990;65:432-440
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FIGURE 6. Coronary heart disease death rates in the United
States from 1977 to 1987. From National Heart, Lung, and
Blood Institute.
The total yearly economic cost of coronary heart
disease to the United States has been estimated.
The direct medical care cost for coronary heart
disease is quoted by the NIH as $15.3 billion in
1987. The total economic cost of coronary heart
disease is estimated to be $54.7 billion annually.
When compared with an annual NHLBI budget of
slightly over $1 billion, it is obvious that a major
increment in the research budget is justified to
combat coronary and other forms of cardiovascular
disease. Despite this perceived need, the percent of
the gross national product and of the federal health
care budget targeted for basic research and devel-
opment has steadily diminished. For example, in
1967, nearly 3% of the health care budget was
assigned to research and development, compared
with only 1.6% in 1987 (data from NIH). Over the
same period of time, while constant dollars for the
NIH increased by 23%, defense research and devel-
opment dollars increased by 112%.
3. Is the result of basic research quantifiable with
respect to the economy?
Number per
1,000 Population
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301
20
FIGURE 7.
States from
Blood Institi
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Coronary heart disease prevalence in the United
1977 to 1987. From National Heart, Lung, and
ite.
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FIGURE 8. Coronary heart disease morbidity costs in the
United States from 1977 to 1127 From NationalHea1t9 Lung,
and Blood Institute.
To answer this question, the relation of research to
patents was reviewed. As an example, the relation of
prostaglandin research to the generation of patents
has been quantified.6 Of 1,778 papers identified for
review by the investigators, 25.3% identified the NIH
as the source of research support. The National
Science Foundation supported 3.1% and various
foreign sources supported 10.1%. Figure 9 shows the
relation between published research and the appear-
ance of patents. As the authors noted, the number of
basic papers peaked before the patents, and a tem-
poral relation between papers and patents is readily
identifiable.
Given the relation between basic research and the
development of patents, what is the economic market
under consideration? The worldwide pharmaceutical
market is estimated to be $80 billion per year;
cardiovascular drugs account for 20% of that
market.7 This represents a thriving industry that has
a major impact on the national health, both medical
and economic.
Any threat to the basic research community
affects this industry in at least three ways. First, the
general awareness of reduced funding for research
as well as excellent opportunities in other disci-
plines (e.g., law and business) has led to shifts in
career interest from science to other fields of
endeavor, resulting in the loss of talented young
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FIGURE 9. Age of cited papers on chemistry ofprostaglan-
dins and relation to filing ofprostaglandin patents. Adapted
from Carpenter et al6 with permission.
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FIGURE 10. United Statespatent awards to non-US citizens.
From Anderson.9 Reproduced with permission.
scientists. Second, as training grants are limited, the
number of industry scientists will be reduced and
the influx of investigators highly trained in state-of-
the-art approaches to important research questions
will decline as well. Third, we are at the dawn of a
new era in basic research in which techniques such
as molecular biology are rapidly expanding our
vistas. To whatever extent basic research is limited
by the federal government, the raw ideas that result
in the generation of patents will be similarly lim-
ited. Data to predict the extent and rapidity of the
adverse effects that will result from current federal
funding policies are not available, but all indica-
tions are that progress will be markedly slowed.
4. What is the relation of foreign to domestic
activities in basic research, and what is the impact
of this relation on the scientific community and
industry?
Stossel and Stossel1 recently reported the countries
of origin of what was considered high-quality clinical
research. They reviewed papers published over a
period of nearly 10 years in theNew EnglandJoumal of
Medicine, Journal of Clinical Investigation, Lancet, and
Blood. The observed changes differed among the
various journals, but overall, the proportion of papers
originating outside the United States increased two-
fold to threefold, with Japan and the countries of
Western Europe being the major contributors. A
similar phenomenon was seen at the AHA's 62nd
annual Scientific Sessions in 1989. More than 8,000
abstracts were submitted for presentation. For the
first time since Scientific Sessions data have been
gathered, the number of submissions from the United
States decreased (by approximately 4%), whereas
those from foreign countries increased by 31%. Again,
the greatest number came from Japan and Western
Europe.
Given the information provided earlier in this
report, it is reasonable to consider the impact of the
increment in research activity outside the United
States on the generation of patents both inside and
outside the country. Recently published data9 indi-
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FIGURE 11. Comparison of US and Japanese patent classes
from 1975 to 1979 and 1980 to 1984. Adaptedfrom Narin and
Olivastro10 with pertnission.
cate that 80% of patents filed in the United States
until 1970 were derived from US sources. As of
1989, the US share has fallen to 50%. As seen in
Figure 10, Japan's contribution to the patent mar-
ket is climbing steeply and not at the expense of the
Federal Republic of Germany, the United King-
dom, France, or other countries. This same ten-
dency can be observed by reviewing the 1989 data
from the Journal of Cardiovascular Patents, which
reviews only patents considered particularly prom-
ising in the cardiovascular area. Thirty-eight per-
cent of these patents were issued for US companies,
18% for Japanese companies, and the remaining
44% for other countries (primarily the Federal
Republic of Germany, the United Kingdom, and
France). While these figures are not sufficient to
permit conclusions about trends in the development
of promising cardiovascular patents, they do not
demonstrate particular dominance on the part of
the United States.
Perhaps the most telling data are those in Figure
11. Narin and Olivastro10 reviewed patent classes
with more than 500 patents each and reported the
change observed when comparing the United States
and Japan from 1975 to 1979 and 1980 to 1984. The
major share of patents was in the sector that identi-
fied a decline in the United States and an increase in
Japan. It must be emphasized that this figure does
not specifically relate to bioaffecting drugs, but
rather, broad classes of patents. Nonetheless, the
overall trend is unmistakable: The United States has
lost its dominance.
In summary:
* There is a quantifiable relation between federal
dollars spent on research funding and the number of
scientific papers published.
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* The performance of basic research, including a
sizeable subset with absolutely no clinical goals, is
clearly necessary for advancement of clinical care.
* The performance of basic research is a cost-
effective means for reducing dollars lost in health-
care expenses and to the economy as the result of
illness and death.
* Compared with other competitive countries, US
efforts are lagging in training of students and scien-
tists and in the generation of scientific information
and its industrial application.
* While this report has focused on research related
to treatment of cardiovascular disease, it has not
addressed in corresponding detail research that has
led to advances in diagnostic modalities. If a compa-
rable analysis of that area were undertaken, a similar
set of health care and economic arguments would
probably be forthcoming.
* Given these unmistakable trends, and despite
the fact that the United States is still in a strong
position, it is reasonable to assume that if federal
support for research is not substantially increased,
this country will be unable to sustain its leadership in
research and development in many areas, including
cardiovascular research. The United States will then
have to look elsewhere for leadership in health care
research and delivery as well as the economic gains
that derive from and are associated with it. In fact,
we will be purchasing from others that which we, to
date, have provided with great success.
Early in the deliberations of the task force, it
became clear that two different but not mutually
exclusive approaches to the present crisis are avail-
able to the AHA. One involves rapid mobilization
and reaction to the present crisis, directed at alert-
ing the nation about the dire impact of present
federal research funding policies on this country's
health and economy. This effort was undertaken by
the AHA on its own in the summer of 1990, with the
goal of reversing federal funding restrictions,
restoring research grant budgets to levels recom-
mended by peer review committees, and increasing
the funding base so that all grants graded outstand-
ing, excellent, or good are funded. This result
should be attained in a setting in which the current
trend toward increased 5-year funding is main-
tained and in which cutbacks in training grants are
reversed.
To achieve this goal, the Ad Hoc Group for
Medical Research Funding has stated:
A stable base of funding will be achieved when we
have assured a steady supply of new creative
researchers who enter productive careers; supported
the best ideas they propose as judged by merit review
and award of the top 50% of approved grant appli-
cations; insured that retiring scientists are replaced
to achieve a steady state; and provided proper equip-
ment and facilities for this cadre of scientists.... An
optimal steady state will be achieved when the
federal research effort is one quarter to one third
larger in constant dollars than at present.... Federal
funding policy should be to increase the annual
appropriations for both NIH and ADAMHA by
2-3% in real growth above the current services
budget for that year. Thus the constant dollar budget
base...would be 25-35% greater by the year 2000
than at present.
This goal for the NIH could satisfy the specific
needs for cardiovascular research funding. Trans-
lated into fiscal year 1991 funding, the Ad Hoc group
has recommended (and the AAMC has endorsed) an
NIH budget of $9,237 billion ($1.6 billion greater
than that in 1990 and $1.3 billion greater than that
requested by the administration).
The second approach can be carried out solely by
the AHA, but the task force views this as better
performed with other interested and appropriate
organizations. Succinctly stated, the United States
needs a 10-year plan for research management. The
current system, in which investigators and NIH
institute directors alike are subject to the whims of
the executive branch and Congress, is in disarray
and unable to develop a plan. In fact, planning in
the face of stringent budget cuts becomes a matter
of attempting to survive rather than encouraging
the reflection and innovation needed for scientific
discovery.
This approach requires that a blue-ribbon panel be
convened under the aegis of a group of organizations.
The committee would produce a position paper
directed at federal-level research management (tar-
geted only to the NIH or to other agencies as well).
Such a report would take 1 or 2 years to prepare.
When adopted by the sponsoring organizations, it
would be used to influence the executive and legis-
lative branches of government to provide a more
stable and hospitable environment for the growth of
scientific research.
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